Mantra Bio Raises $9 Million In Series A-2 Financing To Advance Development Of Lead Targeted Exosome Therapeutics Program
Mantra Bio Raises $9 Million In Series A-2 Financing To Advance Development Of Lead Targeted Exosome Therapeutics Program
01/04/23, 2:03 PM
Location
san francisco
Money raised
$9 million
Industry
therapeutics
artificial intelligence
biotechnology
manufacturing
Round Type
series a
Mantra Bio today announced it has raised $9 million in a Series A-2 financing to advance the development of its lead targeted exosome therapeutics program. New investor, Samsung Securities, joined existing investors, including 8VC, Viking Global Investors, Illumina, BoxGroup and Allen & Company in the financing round. The company's overall Series A funding, including a $25 million Series A-1, totals $34 million.
Company Info
Location
455 mission bay blvd south
san francisco, california, united states
Additional Info
Mantra Bio is developing next generation, targeted therapeutics based on its proprietary exosome engineering platform, REVEAL™. The REVEAL™ platform, which integrates computational biology and bench lab automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics can be reproducibly made at high purity, consistency, and yield. The company's initial pipeline includes engineered exosome therapeutics in the areas of ophthalmology and infectious diseases. Investors include 8VC, Viking Global Investors, Samsung Securities, BoxGroup, Allen & Company LLC, and Illumina. Learn more about Mantra Bio at www.mantrabio.com